https://www.selleckchem.com/products/nu7026.html
erion in the peer-review process of research articles. Statins are the mainstay of treatment for low-density lipoprotein cholesterol (LDL-C) lowering, however, some patients cannot tolerate statins because of adverse effects. Ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are alternative treatment options. The purpose of this meta-analysis is to compare LDL-C reduction with ezetimibe vs PCSK9i in patients not on statins. PubMed and EMBASE were searched until 14 March 2020 for randomized clinical trials (R
إعجاب
علق
شارك
